The project devoted to the development of a cost-effective vaccine against cerivcal cancer, called Cervipro, continues progressing after the meeting held last week among Elena de la Torre, Project Manager at Bionaturis, and the representatives of the German Cancer Research Center (DKFZ) and the company BioEnergy GmbH & Consultant, as leaders of the consortium.

The meeting, held in the facilities of the research center in Heildelberg (Germany), was useful to monitor the contributions and actions of each member, as well as to set the next milestones in the development. Besides our Project Manager, Elena de la Torre, the attendees were Michael Götz (from BioEnergy GmbH & Consultant), Martin Müller and Caroline Odenwald (from DKFZ).

The goal of the Cervipro Project is to obtain a cost-effective vaccine against the Human Papilomavirus, which causes the cervical cancer. This project receives funding from the Eurostars-2 Programme with co-funding from CDTI and the Research and Innovation Horizon 2020 Framework Programme from European Union.

Taking part in an alternative strategy to produce the drug in a cost-effective way to make it affordable for the most highly impacted regions, Bionaturis Group is following its vision of ‘A Global Access To Health’.

About Bionaturis

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).